ClinicalTrials.gg
Not yet recruitingNCT06841965Updated Feb 24, 2025

Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer

A Phase 3 interventional study of Intravenous thrombolysis in Stroke and Acute Ischemic Stroke, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies testing thrombolytics in Ischemic Stroke — 41 open to participants now, 41 under way, 31 of them phase 3. A drug class: Thrombolytics · Ischemic Stroke.

Planned enrollment
56th of 101
280 · median 324
Started
2025
with 15 others
Phase 3
54 of 101
29 open now
Primary completion
2027-06
later than 13 of 40 live
Registered
75th of 101
by date
Lead sponsor
5 of 101
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 101 studies testing thrombolytics in Ischemic Stroke, this one is the 56th largest by planned enrollment, is one of 16 that started in 2025, is one of 54 in phase 3, reaches primary completion later than 13 of the 40 other live ones, and was the 75th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

41 of the 101 studies testing thrombolytics in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

36 more — sign in →

By country, each count listing its studies:

All 41 open studies →

About thrombolytics

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing thrombolytics in Ischemic Stroke, or all of them as a file.
02

Study summary

The primary hypothesis being tested in this trial is that ischemic stroke patients with active cancer will have improved clinical outcomes when given intravenous thrombolysis compared to standard care.

03

Conditions studied

  • Stroke
  • Acute Ischemic Stroke

Browse trials for

04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 280 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with clinical signs of acute ischemic stroke within 24 hours of onset or awakening with stroke (if within 24 hours from the midpoint of sleep). Patients with AIS within 4.5-24 hours of onset must meet the IVT inclusion criteria specified in the guideline
  2. Patients with active cancer (Active cancer was defined as cancer diagnosed within the previous 6 months; recurrent, regionally advanced or cancer, or cancer for which treatment had been administered within 6 months, or haematological cancer without complete remission.)
  3. Patients ≥ 18 years old
  4. has been obtained depending on local ethics requirements.

Exclusion criteria

Exclusion Criteria:

(1) Intended to proceed to endovascular treatment; (2) Pre-stroke mRS score > 2 (3) for IVT:

  1. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hematoma, etc.)
  2. Previous history of intracranial hemorrhage
  3. Severe head trauma or stroke history within the last 3 months
  4. Intracranial tumors, giant intracranial aneurysms
  5. Intracranial or spinal surgery within the recent 3 months
  6. Major surgical procedures within the last 2 weeks
  7. Gastrointestinal or urinary tract bleeding within the last 3 weeks
  8. Active visceral bleeding
  9. Aortic arch dissection
  10. Arterial puncture in a site within the last 1 week that is not easy to compress and stop bleeding
  11. Elevated blood pressure: Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg
  12. Acute bleeding tendency, including count \< 100 × 10⁹/L or other conditions
  13. Received low-molecular-weight heparin treatment within 24 hours
  14. Oral anticoagulants (warfarin) with > 1.7 or PT > 15 s; Receiving heparin treatment with aPTT above the within the last 24 hours of onset, Receiving thrombin inhibitors and factor Xa inhibitors within the last 48 hours of onset.
  15. Blood sugar \< 2.8 or > 22.22 mmol/L
  16. Head CT or MRI indicates large-area infarction (infarction area ≥ 1/3 of the middle cerebral artery supply area) (4) The judgment is left to the discretion of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents))

    Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg),intravenous Tenecteplase(0.25mg/kg,administered as a single intravenous bolus injection over 5 - 10 seconds,with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

    Drug: Intravenous thrombolysis

  • No intervention
    Standard therapy

    Standard therapy

Interventions

  • DrugThrombolyticsStudies of ThrombolyticsThrombolytics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg),intravenous Tenecteplase(0.25mg/kg,administered as a single intravenous bolus injection over 5 - 10 seconds,with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

07

What researchers measure

Primary outcomes

  1. Independent recovery assessed by ratio of modefied Rankin Scale (mRS) score of 0-2 (%) at 90 ± 7 days

    mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

    Time frame: 90 ± 7 days

Secondary outcomes

  1. Excellent recovery assessed by the ratio of modified Rankin Scale (mRS) score of 0-1 (%) at 90 ± 7 days

    mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

    Time frame: 90 ± 7 days

  2. recovery assessed by modefied Rankin Scale (mRS) score

    mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

    Time frame: 90 ± 7 days

  3. 3-month mortality

    Hospitalization records or follow-up results

    Time frame: 90 ± 7 days

  4. Presence of parenchymal hemorrhage (PH) evaluated by CT or MRI

    the presence of PH is defined according the standard from ECASS-2 study

    Time frame: at day 1

  5. Presence of symptomatic intracerebral hemorrhage (sICH) evaluated by CT or MRI

    the presence of sICH is defined according the standard from ECASS-2 study

    Time frame: at day 1

  6. Presence of hemorrhagic transformation evaluated by CT or MRI

    Presence of hemorrhagic transformation is defined according the standard from ECASS-2 study

    Time frame: at day 1

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No — Protecting the privacy of participants is a priority, and sharing IPD could potentially compromise this.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jun 2027, 27 months later.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 27 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Feb 24, 2025
StartEst.
Mar 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06841965
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 1, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 24, 2025

Study contacts

Min Lou, PhD, MD
Contact
lm99@zju.edu.cn
8613958007213
Wansi Zhong, MD
Contact
21718233@zju.edu.cn
8618757155806
Min Lou, PhD, MD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thrombolytics

Start the discussion